2 results match your criteria: "Center for Medical Education and Clinical Research CEMIC. University Hospital[Affiliation]"
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.
J Immunother Cancer
August 2024
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Article Synopsis
- Checkpoint inhibitor therapy, particularly nivolumab combined with ipilimumab, shows promise for patients with high tumor mutational burden (TMB-H) across various tumor types, indicating a potential survival benefit.
- The study involved 201 patients with advanced solid tumors who were resistant to standard treatments; they were randomly assigned to receive either the combination of nivolumab and ipilimumab or nivolumab alone, with the effectiveness measured based on objective response rates.
- Results demonstrated higher response rates in patients with TMB-H tumors who received the combination therapy, and the safety profile was acceptable, suggesting this treatment could be beneficial for patients with limited options.
Prenatal screening for chromosome abnormalities in a region with no access to termination of pregnancy.
Prenat Diagn
July 2009
Department of Psychiatry, Center for Medical Education and Clinical Research CEMIC. University Hospital, Buenos Aires, Argentina.
Objective: To analyze the different variables that affect couples' decision-making about prenatal screening of chromosome abnormalities in a population with limited access to prenatal diagnosis and no legal termination of pregnancy (TOP).
Methods: From February through August 2004, 79 couples who requested for prenatal screening at centers from Argentina and Uruguay participated in a study. A cross-sectional survey was administered to assess attitudes toward prenatal screening, the decision-making process, and knowledge and attitudes toward TOP.